Dexela fund raising of £2.6 Million

Dexela Limited, the London-based company developing accurate and sensitive 3D imaging technology known as Tomosynthesis, focused initially on the early detection of breast cancer, is pleased to announce that it has raised more than £2.6 million through the issue of shares. The main investors in this funding round included Close Ventures and London Technology Fund.

The proceeds of the fundraising will be used to support the ongoing development and commercialisation of Dexela’s imaging technology.

The early detection of breast cancer using screening mammography significantly reduces mortality, however screening mammography still has a significant rate of both false negative and false positive results, particularly in younger women. Dexela’s technology aims to reduce the number of both false negatives and false positives and thus detect breast cancer earlier while reducing the occurrence of patient call-backs.

Dexela has developed a leading intellectual property position covering powerful methods to acquire, process and visualise data from 3D X-ray breast imaging. The Company is collaborating with medical device manufacturers to bring its technology into clinical practice. Dexela has raised more than £4.7 million to date via two funding rounds and grants.

Edward Bullard, Chief Executive of Dexela, said: “I am very pleased to have raised these funds with such high quality investors. Over the past year Dexela has achieved considerable progress and we hope to be able to build on this strong foundation in the future. Dexela believes that its technology will contribute significantly to the improvement of breast cancer screening and diagnosis, including outcomes and cost, around the world.”

Andrew Elder, Director of Close Ventures, said: “We are pleased to have participated in this funding round and are excited about the future prospects of Dexela. Dexela’s breast imaging technology has the potential to contribute where there is a major area of unmet diagnostic and medical need.”

For more information about Dexela Ltd, please contact:

Dexela Limited
Edward Bullard, Chief Executive
Tel: +44 (0) 20 7148 3107


Close Ventures
Andrew Elder
Tel: +44 (0)20 7422 7832
Buchanan Communications
Mary-Jane Johnson, Catherine Breen
Tel: +44 (0) 20 7466 5000


Notes for Editors

About Dexela Limited
Dexela is developing accurate and sensitive 3D breast imaging technology for the early detection of cancer, known as Tomosynthesis. Conventional mammography has a significant rate of both false negatives and false positives, particularly in younger women. Dexela is developing innovative technology for 3D breast imaging, which promises to significantly reduce both false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of call-backs. Dexela has developed powerful techniques to acquire, process and visualize data from 3D X-ray breast imaging. Dexela is playing a central role in this field through relationships with medical device manufacturers.

For more information about Dexela Ltd please visit www.dexelaimaging.com.

Incidence of Breast Cancer
Breast cancer is the most common cancer in the UK. Each year, there are over 44,000 new cases and over 12,000 deaths from this disease. The lifetime risk for a woman of developing breast cancer is one in nine (11%). Breast cancer survival rates are better the earlier the cancer is diagnosed. Around 9 out of 10 of women diagnosed with stage I breast cancer survives beyond five years. This drops to around 1 out of 10 diagnosed with stage IV.

________________________________________

This e-mail is confidential and may also be legally privileged. If you are not the intended recipient, please contact us.
Dexela Limited
Registered Office: 23 Rochester Terrace, London, NW1 9JN
Registered in England no. 4797594